MAM
Interface Communications’ M Ganesan joins Group M
MUMBAI: Group M has just made a senior recruitment in their central trading group (CTG) unit. M Ganesan, who was with Interface Communications in Chennai as head of buying, has joined CTG’s Delhi arm as investment director.
Ganesan will be reporting to Group M’s national director central trading group Lakshmi Narasimhan.
Ganesan’s job role includes the all India buying for all the regional networks as well as strategic inputs and ideation across channels. Client interfacing will also be a part of Ganesan’s job role.
Commenting on the appointment, Narasimhan states, “Ganesan comes with a good number of years of experience in the media space. He is a senior professional who worked with us earlier in the late nineties. With Ganesan joining us, we hope to use his regional understanding and leverage it to our advantage.”
Talking about the shift, Ganesan points out, “Joining Group M is definitely a larger opportunity. I will be handling clients like Pepsi, Gillete and GSK. Also the regional responsibility is something that is very big, and working with Group M will definitely be a great learning experience.”
Group M was on the look out for an investment director for a while, and Ganesan’s appointment comes after months of head hunting.
Prior to Interface, Ganeshan was with Initiative media for a year. He has a total of 15 years in the industry. At Interface Chennai, Ganeshan was handling the Henkel account and was the buying head.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
